Endometrial carcinoma: pathology and genetics
- 1 February 2007
- journal article
- review article
- Published by Elsevier BV in Pathology
- Vol. 39 (1), 72-87
- https://doi.org/10.1080/00313020601136153
Abstract
In the Western world, endometrial carcinoma is the most common malignant tumour of the female genital tract and the fourth most common cancer in women after carcinomas of breast, colorectum, and lung. The annual incidence has been estimated at 10-20 per 100 000 women. In the United States, endometrial carcinoma accounts for approximately 6000 deaths per year. Two different clinicopathological subtypes are recognised: the oestrogen-related (type I, endometrioid) and the non-oestrogen related (type II, non-endometrioid). The clinicopathological differences are parallelled by specific genetic alterations, with type I showing microsatellite instability and mutations in PTEN, PIK3CA, K-Ras, and CTNNB1 (β-catenin), and type II exhibiting p53 mutations and chromosomal instability. This article reviews the genetic changes of endometrial carcinogenesis in the light of morphological features of the tumours and their precursors.Keywords
This publication has 153 references indexed in Scilit:
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Mutation of the PIK3CA oncogene in human cancersBritish Journal of Cancer, 2006
- Frequent Mutation of the PIK3CA Gene in Ovarian and Breast CancersClinical Cancer Research, 2005
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- RAS/RAF mutation and defective DNA mismatch repair in endometrial cancersAmerican Journal of Obstetrics and Gynecology, 2004
- Molecular alterations associated with cyclin d1 overexpression in endometrial cancerInternational Journal of Cancer, 2004
- Nuclear β‐catenin is a molecular feature of type I endometrial carcinomaThe Journal of Pathology, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997